Fibrillar Absorbable Hemostat: A Promising Aid for Bleeding Control in Colorectal Tumors

Colorectal cancer, one of the most common cancers worldwide, typically needs sophisticated treatment modalities to achieve optimal results. Amongst these, endoscopic submucosal dissection (ESD) has emerged as an appealing method for the early-stage management of colorectal tumors. However, the procedure's success can be tempered by postoperative complications such as postponed bleeding and perforation, in addition to the challenge of handling big mucosal defects. Moreover, direct exposure to gastrointestinal flora increases the risk of bacteremia and endotoxemia. In the mission for safer and more reliable services, researchers and clinicians are constantly exploring alternative techniques. Fibrillar absorbable hemostat such as Surgicel ® Fibrillar ™ (Ethicon), however, becomes a game-changer provides a multifaceted approach to post-ESD care, offering both hemostatic support and localized bactericidal impacts.

A notable item in this realm is Surgi-ORC ® Fibril from Aegis Lifesciences, including the following key qualities:

Key Features of Surgi-ORC ® Fibril:

• Lightweight, tufted, soft and layered structure
• Provides high flexibility and conformability to surgical sites
• Suitable for irregular shaped injuries and hard-to-reach areas
• Bactericidal properties
• Soft, layered material adheres and "melts in" to bleeding tissue
• Completely absorbable
• 7 layers fibrillose fabric
• Designed for hemostasis in

How does Surgi-ORC ® Fibril Work?
Surgi-ORC ® Fibrilis made up of oxidized regenerated cellulose, which, upon contact with blood, swells into a gelatinous mass, helping in embolisms formation and avoiding further bleeding. Furthermore, its low pH of 3.4 displays potent bactericidal properties, reducing the risk of infection considerably.

Clinical Study Results:

A clinical study was conducted at the University of Soonchunhyang Hospital in Bucheon, Korea, sheds light on the efficiency of Surgicel ® Fibrillar ™ in colorectal ESD. In an accomplice of 49 clients, Surgicel ® Fibrillar ™ was effectively applied to cover the entire mucosal defect following ESD, without any Surgicel-related issues. Remarkably, none of the patients in the Surgicel group experienced delayed bleeding or perforation, marking a substantial improvement over conventional ESD methods. Furthermore, Surgicel ® Fibrillar ™ was related to much shorter healthcare facility stays and lower inflammatory markers, showing quicker healing and enhanced postoperative results.

Fig. 1: A) Lateral spreading tumor; B) Dissected colon LST by colon endoscopic Fibrillar Absorbable Hemostat submucosal dissection.; C) Surgicel was placed onto the mucosal defect to cover the entire mucosal defect; D) Surgicel swelled into a gelatinous mass [1]

Conclusion:

In the realm of colorectal cancer treatment, every development brings us closer to our ultimate goal: enhancing client results and improving lifestyle. Fibrillar absorbable hemostat represents a critical turning point in this journey, using a powerful mix of hemostatic effectiveness and antimicrobial security. As we continue to press the limits of development, let us accept the transformative potential of Fibrillar absorbable hemostat and embark on a path towards safer, more effective colorectal endoscopic resection.

Referrals:

[1] Myung YS, Ko BM, Han JP, Hong SJ, Jeon SR, Kim JO, Moon JH, Lee MS. Effectiveness of Surgicel® (Fibrillar) in patients with colorectal endoscopic submucosal dissection. Surgical endoscopy. 2016 Apr;30:1534-41. DOI:10.1007/s00464-015-4369-5


Article Tags: Fibrillar Absorbable Hemostat, Fibrillar Absorbable Topical Hemostat.